Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
Beacon of Hope CRO is working with sponsors and other service providers to design Right to Try treatment programs, which the company’s founder says have ‘unmatched’ flexibility, an ability to treat screen fails and create ‘interim clinical milestones,’...
US FDA approves AstraZeneca’s at-home autoinjector for administration of an add-on treatment for severe asthma, matching the indication of GSK’s rival product, Nucala.
Three organizations have merged to form Apex Innovative Sciences, an independent clinical trial site operator focused on Phase I-IV studies for central nervous system indications and other therapeutic areas, including neurology, psychiatry, addiction,...
Through a recently announced partnership with TrialSpark, 23andMe has entered the clinical trials market – an area in which the direct-to-consumer genetic testing company feels it has the potential to grow.
Parexel increases its real world data network by more than 330m patients across 60 health care and consumer sources though a partnership with HealthVerity – which earlier this year raised $25m to advance its technology.
Datacubed Health today launches the Linkt Location app, which tracks participant interactions with health care facilities, providing reminders and other communications to garner insight into health events that are often unreported.
A partnership between Sciex and Protein Metrics aims to make their services compatible with other software services available, enabling drug developers to work in an ‘open ecosystem.’
The recently-launched Research on Research Institute aims to deliver “transformative and translational research on research systems, cultures, and decision-making,” the need for which “has never been more vital,” says director.
After an investigation last year, the FDA cites problems across multiple sites within the Lupin manufacturing network, raising questions about ‘management oversight and control’.
US FDA expands the approval of Gilead’s Descovy to make it available for the PrEP indication, coming ahead of the entrance of generic rivals to the company’s Truvada product.
England’s High Court throws out the claim that Sandoz’s inhaler product passed off the appearance of GSK’s rival through its use of the color purple in packaging.
Iqvia’s Orchestrated Patient Engagement solution, powered by Belong.Life, delivers ‘hyper-personalized’ content to engage and support patients, providing insights that will benefit patients, life sciences companies, and the health care system, says CEO.
CAS collates the world’s largest collection of formulations – a ‘one-stop-shop’ that will help formulators innovate faster and solve problems, ultimately reducing drug development timelines, says project lead.
Phastar is building up its data science group as AI and machine learning ‘are rapidly modernizing clinical trials’ and Synteract boosts its centers of development in oncology and rare/orphan diseases, among other people on the move this month.
Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
LGC announces the addition of Quanterix’s HD-X platform to its offering, enabling automated development and performing of immunoassays for ‘unprecedented insights’ into disease biology as well as drug efficacy and safety.
Partnering with airlines is essential, says CSafe executive, as the company signs an agreement to use LOT Cargo’s to airplanes to transporttemperature-sensitive biologics.
LMC Manna is expanding its ability to provide clinical research as a care option to patients by integrating research within its clinics and physician practices – changing the dynamic of how research exists in Canada, says company executive.
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
Johnson & Johnson reaches $20m settlement with two US counties on lawsuits regarding the opioid crisis, exits the upcoming federal trial involving several drug manufacturers.
With nitrosamines back in the headlines due to the recent discovery of contaminants in ranitidine, the EMA releases the five potential causes of the impurities plaguing the industry.
AstraZeneca is implementing N-Side’s recently launched Suite for Clinical Trials to provide ‘a single source of truth’ for safely supplying trials, as more stakeholders are generating more data.
AstraZeneca enters a $270m deal with Cheplapharm to divest seven drugs, in order to reduce its portfolio of ‘mature’ medicines and reinvest in other therapeutic areas.
Rho experts speak to the challenges facing drug development, meeting unmet needs, quality by design, and advances in technology, among other topics, during a sit-down at the CRO’s headquarters.
Hospital Angelina Caron of Campina Grande do Sul, Paraná has nearly one million patients, making it the largest hospital in Brazil to join Clinerion’s network.
Firma Clinical Research collaborates with patient advocates to integrate patient-specific information into its clinical trial patient care partner training program, as the company conducts more procedures in-home 'than ever before.'
In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.
The Friends of Cancer Research, in collaboration with Iqvia and other health care research organizations, are working to determine where and when real-world data can be trusted.
US FDA follows up the first generic approval of naloxone nasal spray by encouraging companies to apply with generic applications amid the North American opioid crisis.
PRA Health Sciences’ wholly-owned subsidiary, Symphony Health, has launched a ‘first of its kind’ national market measurement solution integrating prescriber, patient, and payer insights.
The CRO has opened a new clinic in response to demand for early-stage research, specifically for Alzheimer’s Disease, and expanded its footprint in India to conduct studies ‘at favorable pricing with faster timelines,’ say company executives.
